Captain T Cell GmbH announced the successful closing of a seed financing round totalling EUR 8.5 million. A syndicate of experienced life-science investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H participated in the round. In addition, the German Federal Ministry of Education and Research (BMBF) is supporting the start-up as part of its GO-Bio program.
Captain T Cell develops first-in-class efficacy-enhanced TCR-T cells for solid tumours that are not addressed by existing therapies. A key technology established by the Captain T Cell team is its proprietary TCR-ALLO platform for off-the-shelf treatment of solid tumours. The tool can be expanded to a variety of cancer indications.
The startup builds on years of research and innovations conducted in the labs of the Max Delbrück Center on Campus Buch and utilizes technologies developed there. Ascenion, as the MDC’s technology transfer partner, supported the Captain T Cell team for several years before the company was founded, and negotiated the license agreement with Captain T Cell for the MDC. Both the MDC and Ascenion remain close partners of the founding team.
Further information:
MDC's press release
Ascenion’s portfolio company Captain T Cell secures EUR 8.5 million in seed financing
Captain T Cell, a spin-off from the Max Delbrück Center (MDC), focuses on developing T cells to target solid tumours. The funds are intended to expedite the development and deployment of a new generation of T-cell therapies in clinical settings.
